A Phase 2/3 interventional study of DNL343 and Matching Placebo in Amyotrophic Lateral Sclerosis, sponsored by Merit E. Cudkowicz, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Merit E. Cudkowicz, MD · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 33rd largest by enrollment of the 307 interventional ones that give a count, is one of 12 that started in 2023, is one of 18 in phase 2/3, and was the 341st registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 249 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
Merit E. Cudkowicz, MD is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
Merit E. Cudkowicz, MD has 9 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen G will evaluate the safety and efficacy of a single study drug, DNL343, in participants with ALS.
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683. Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.
If a participant is randomized to Regimen G DNL343, the participant will complete a screening visit to assess additional Regimen G eligibility criteria. Once Regimen G eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active DNL343 or matching placebo.
Regimen G will enroll by invitation, as participants may not choose to enroll in Regimen G. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen G.
For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DNL343
Drug: Matching Placebo
DNL343 is administered orally once daily per day for 24 weeks.
Matching placebo is administered orally once daily per day for 24 weeks.
Disease Progression as Assessed by the ALSFRS-R-Slope
Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4(normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function. Note that only participants who survived to their Week 24 visit contribute to the estimate.
Time frame: Baseline to 24 Weeks
Mortality Event Rate
The Mortality Rate, presented as mean deaths per month, was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times. Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row.
Time frame: Baseline to 24 weeks
ALSFRS-R Total Score
Change in ALSFRS-R total score over time. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function.
Time frame: Baseline to 24 Weeks
Combined Assessment of Function and Survival (CAFS)
Combined assessment of function and survival (CAFS) ranks participants' clinical outcomes based on survival time and change in the functional score. Each participant's outcome is compared to every other participant's outcome, assigned a score, and the summed scores are ranked. The mean rank score for each treatment group can then be calculated. A higher mean CAFS rank score indicates a better group outcome. The survival outcome is death or death-equivalent, where a participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The functional outcome is the ALS Functional Rating Scale-Revised (ALSFRS-R) score with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function.
Time frame: Baseline to 24 Weeks
Respiratory Function
Change in respiratory function over time as assessed by slow vital capacity (SVC)
Time frame: Baseline to 24 Weeks
Upper Limb Muscle Strength
Change in upper limb muscle strength over time as measured isometrically using hand-held dynamometry and grip strength, calculated as the average percent change from baseline of the following muscles/maneuvers: shoulder flexion, elbow flexion, elbow extension, wrist extension, abductor pollicis brevis contraction, abductor digiti minimi contraction, first dorsal interosseous contraction, and grip strength. Note that only those with measurable strength at baseline were included.
Time frame: 24 weeks
Number of Participants With Death or Permanent Assisted Ventilation (PAV)
The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.
Time frame: Baseline to 24 weeks
Number of Participants Who Experience Death
The number of participants who died from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline).
Time frame: Baseline to 24 weeks
Disease Progression Biomarker
Change in log-transformed serum neurofilament light protein (NfL) concentration from baseline to Week 24
Time frame: Baseline to 24 weeks
| Milestone | DNL343 | Matching Placebo |
|---|---|---|
| Started | 186 | 63 |
| Completed | 156 | 55 |
| Not completed | 30 | 8 |
Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4(normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function. Note that only participants who survived to their Week 24 visit contribute to the estimate.
| Percent change | DNL343 | Matching Placebo |
|---|---|---|
| Disease Progression as Assessed by the ALSFRS-R-Slope | -0.84 ± 0.075 | -0.87 ± 0.060 |
Change in ALSFRS-R total score over time. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function.
| Points | DNL343 | Matching Placebo |
|---|---|---|
| ALSFRS-R Total Score | -5.87 ± 0.44 | -5.46 ± 0.52 |
Combined assessment of function and survival (CAFS) ranks participants' clinical outcomes based on survival time and change in the functional score. Each participant's outcome is compared to every other participant's outcome, assigned a score, and the summed scores are ranked. The mean rank score for each treatment group can then be calculated. A higher mean CAFS rank score indicates a better group outcome. The survival outcome is death or death-equivalent, where a participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The functional outcome is the ALS Functional Rating Scale-Revised (ALSFRS-R) score with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function.
| Rank | DNL343 | Matching Placebo |
|---|---|---|
| Combined Assessment of Function and Survival (CAFS) | 152.89 ± 9.22 | 162.05 ± 7.02 |
Change in respiratory function over time as assessed by slow vital capacity (SVC)
| 24-week diff. of percents of normal VC | DNL343 | Matching Placebo |
|---|---|---|
| Respiratory Function | -12.22 ± 1.46 | -9.68 ± 1.61 |
Change in upper limb muscle strength over time as measured isometrically using hand-held dynamometry and grip strength, calculated as the average percent change from baseline of the following muscles/maneuvers: shoulder flexion, elbow flexion, elbow extension, wrist extension, abductor pollicis brevis contraction, abductor digiti minimi contraction, first dorsal interosseous contraction, and grip strength. Note that only those with measurable strength at baseline were included.
| Percent change | DNL343 | Matching Placebo |
|---|---|---|
| Upper Limb Muscle Strength | -33.92 ± 2.42 | -38.32 ± 2.73 |
The Mortality Rate, presented as mean deaths per month, was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times. Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row.
| Events per month | DNL343 | Matching Placebo |
|---|---|---|
| Mortality Event Rate | 0.007 ± 0.0021 | 0.007 ± 0.0020 |
The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.
| Participants | DNL343 | Matching Placebo |
|---|---|---|
| Number of Participants With Death or Permanent Assisted Ventilation (PAV) | 8 | 5 |
The number of participants who died from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline).
| Participants | DNL343 | Matching Placebo |
|---|---|---|
| Number of Participants Who Experience Death | 6 | 4 |
Change in log-transformed serum neurofilament light protein (NfL) concentration from baseline to Week 24
| ng/L | DNL343 | Matching Placebo |
|---|---|---|
| Disease Progression Biomarker | 0.075 ± 0.022 | -0.006 ± 0.026 |
Collected over Up to 35 weeks after participant signed Master Protocol consent. For safety analyses, the analysis populations include all anticipated and unanticipated safety events (i.e. Deaths, Serious Adverse Events, and Other Adverse Events) due to any cause, that occurred or worsened on or after treatment initiation to either the final safety visit, the date of death, the date of last study contact, or the date of first dose of study drug during participation in the ATE period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DNL343 | 6/186 (3.2%) | 28/186 (15.1%) | 149/186 (80.1%) |
| Matching Placebo | 3/63 (4.8%) | 10/63 (15.9%) | 43/63 (68.3%) |
| Event | DNL343 | Matching Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 4/186 | 0/63 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/186 | 1/63 |
| ConstipationGastrointestinal disorders | 1/186 | 1/63 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/186 | 1/63 |
| AppendicitisInfections and infestations | 0/186 | 1/63 |
| BronchitisInfections and infestations | 0/186 | 1/63 |
| Femur fractureInjury, poisoning and procedural complications | 0/186 | 1/63 |
| Limb traumatic amputationInjury, poisoning and procedural complications | 0/186 | 1/63 |
| Traumatic intracranial haemorrhageInjury, poisoning and procedural complications | 1/186 | 1/63 |
| Transverse sinus thrombosisNervous system disorders | 0/186 | 1/63 |
| Event | DNL343 | Matching Placebo |
|---|---|---|
| FallInjury, poisoning and procedural complications | 73/186 | 13/63 |
| Muscular weaknessNervous system disorders | 42/186 | 6/63 |
| FatigueGeneral disorders | 41/186 | 10/63 |
| ConstipationGastrointestinal disorders | 30/186 | 7/63 |
| HeadacheNervous system disorders | 30/186 | 10/63 |
| DiarrhoeaGastrointestinal disorders | 20/186 | 8/63 |
| Urinary tract infectionInfections and infestations | 19/186 | 0/63 |
| NeuromyopathyNervous system disorders | 11/186 | 6/63 |
| NauseaGastrointestinal disorders | 17/186 | 4/63 |
| Muscle contractions involuntaryNervous system disorders | 10/186 | 5/63 |
Baseline Analysis Population includes only placebo participants from the Regimen G Efficacy Regimen Only (ERO) sample; shared placebo participants from other regimens are not included in the Baseline Analysis Population.
| Age, Continuous(Years) | DNL343 | Matching Placebo | Total |
|---|---|---|---|
| Mean | 59.5 ± 11.55 | 57.3 ± 11.92 | 58.94 ± 11.66 |
| Sex: Female, Male(Participants) | DNL343 | Matching Placebo | Total |
|---|---|---|---|
| Female | 82 | 13 | 95 |
| Male | 104 | 50 | 154 |
| Race (NIH/OMB)(Participants) | DNL343 | Matching Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 175 | 61 | 236 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | DNL343 | Matching Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 5 | 20 |
| Not Hispanic or Latino | 169 | 57 | 226 |
| Unknown or Not Reported | 2 | 1 | 3 |
| ALS Diagnosis from R El Escorial Criteria(Participants) | DNL343 | Matching Placebo | Total |
|---|---|---|---|
| Clinically Possible ALS | 20 | 5 | 25 |
| Clinically Probable ALS - Laboratory Supported | 36 | 10 | 46 |
| Clinically Probable ALS | 62 | 26 | 88 |
| Clinically Definite ALS | 68 | 22 | 90 |
| ALS Onset Location(Participants) | DNL343 | Matching Placebo | Total |
|---|---|---|---|
| Axial | 1 | 0 | 1 |
| Bulbar | 29 | 6 | 35 |
| Generalized | 0 | 0 | 0 |
| Limb | 155 | 56 | 211 |
| Multiple | 1 | 1 | 2 |
| Respiratory | 0 | 0 | 0 |
| Time Since Symptom Onset at Baseline(Months) | DNL343 | Matching Placebo | Total |
|---|---|---|---|
| Mean | 19.7 ± 8.05 | 21.0 ± 7.91 | 20.1 ± 8.02 |
| Delay in ALS Symptom Onset and Diagnosis(Months) | DNL343 | Matching Placebo | Total |
|---|---|---|---|
| Mean | 10.3 ± 6.24 | 10.8 ± 5.68 | 10.4 ± 6.10 |
11 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2023 to primary completion in Oct 2024, 17 months.
Results were first posted in Jan 2026, 1 year 2 months after primary completion.
Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evetifator
Amyotrophic Lateral Sclerosis →
Merit E. Cudkowicz, MD